Bruker 6.375% Mandatory Convertible Preferred Stock Series A Stock Earnings Reports

Key points for investors: Bruker reported Q1 2026 revenue of $823.4M (reported +2.7% YoY) driven by M&A and FX tailwinds but with organic revenue down 4.4%. Organic bookings in the Bruker Scientific Instruments (BSI) segment grew high-single-digits and BSI book-to-bill was >1.0x for the third consecutive quarter. Notable growth areas: AI-driven Semiconductor Metrology (now >$300M annualized), SciY lab digitization/software (~$50M), and European/Middle East security detection (~$70M expected revenue). BEST (superconductors, Fusion) secured large multi-year orders (~$600M of multiyear superconductor orders in last 5 months) and BEST organic revenues grew ~3% CER. Margins: Q1 non-GAAP gross margin 50% and operating margin 10.2% (both down YoY but ahead of expectations). Management is executing an expanded cost-savings program and now expects ≈$140M of annualized savings (up from prior $100–$120M target). Cash/Leverage: Q1 operating cash flow $71M, free cash flow $47M, cash ~$133M, $180M of debt paydown in the quarter, net leverage ~2.9x. Guidance: management reconfirmed FY26 guidance — reported revenue $3.57–3.60B (reported growth ~4–5%; organic growth 1–2%), non-GAAP EPS $2.10–2.15 (implying 15–17% growth; CER EPS growth ~23–25%), and expects organic non-GAAP operating margin expansion of ~250–300 bps vs FY25 (300–350 bps organic improvement partially offset by FX/tariff headwinds). Near-term outlook: management expects Q2 organic revenue growth to return (low- to mid-single-digits) and a meaningful sequential margin and EPS step-up in Q2 with continued improvement through H2. Key risks remain FX volatility, tariffs, and weaker U.S. Academic & Government (ACA/GOV) funding (China revenue was down >20% YoY in Q1), but order momentum outside the U.S., and across several idiosyncratic AI/security niches, provide offset and upside potential.